Busulfan and subsequent malignancy: An evidence-based risk assessment.
Janel R Long-BoyleDonald B KohnAmi J ShahSueli Marques SpencerJulian SevillaClaire BoothJosé Luis López LorenzoEileen NicolettiArpita ShahMeredith ReatzJoana MatosJonathan D SchwartzPublished in: Pediatric blood & cancer (2023)
The incidence of busulfan-related secondary malignancies is low, and likely to be substantially less than 1% in pediatric transplant recipients, especially those receiving busulfan monotherapy for nonmalignant conditions other than SCD.